EVALUATION OF SERUM LIPID PROFILE IN TURKISH PATIENTS WITH CHRONIC HEPATITIS C

Yıl 2011, Cilt: 8 Sayı: 1, 7 - 12, 01.03.2011

Mustafa Güçlü Mustafa Güçlü Hakan Sakallı Tolga Yakar Nurzen Sezgin Murat Gülşen

Öz

Anahtar Kelimeler

-

EVALUATION OF SERUM LIPID PROFILE IN TURKISH PATIENTS WITH CHRONIC HEPATITIS C

Öz

-

Anahtar Kelimeler

-

Kaynakça

• Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992;15:572-7.
• Lfkowitch JH, Schiff ER, Davis GL, et al. Pathological di- agnosis of chranic hepatitis C: a multicenter camparative study with chronic hepatitis B. Gasroenterology 1993; 104:595-603.
• Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of chranic hepatitis C. Hepatology 1992;15:567-71.
• Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cellsvia low-density lipoprotein receptor. Proc Natl Acad Sei USA 1996;96:12766-71.
• Monazahian M, Bohme 1, Bonk S, et al. Low densty lipo- protein receptor as a candidate receptorfor hepatitis C virus. J Med Virol 1999;57:223-9.
• Barba G, Harper F, Harada T, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to collular lipid storage droplet. Proc Natl Acad Sci USA 1997;94:1200-5.
• Sabila A, Perlemuter G, Bono F, et al. Hepatitis C virus core protein binds to apolipoprotein Aıı and its secretion is modulated by fibrates. Hepatolgy 1999;30:1064-76.
• Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatiits C virus induced hypobetalipopro- teinemia: a possible mechanism for steatosis in chronic hepatitis. J Hepatol 2001;34:428-34.
• Kyoji Moriya et all. Serum lipid profilo of patients with genotype 1b hepatitis C viral infection in Japan. Hepatology Research 2003; 25: 371-76.
• Parlemuter G, Sabila A, Letteron P, et al. Hepatitis C vi- rus core protein inhibits triglyceride-transfer protein ac- tivity and very low-density lipoprotein secration: amodel of viral-related steatosis. FASEB J 2002;16:185-94.
• Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Steals B. Negative regulation of the human apolipo- protein A-1 promoter by fibrates can be atteunated by the interaction of the proxisome proliferator-activated receptor with its response element. J Biol Chem 1994; 269:31012-8.
• Vu-Dac N, Schoonjans K, Kosykh V, et al. Fibrates increase human apolipoprotein A-II expression through activation of the proxisome proliferator-activated receptor. J Clin Insevt 1995;96:741-50.
• Hwang SJ, Luo JC, Chu CW, et al. Hepatic steatosis in chronic hepatitis C virus infection : Prevalence and clini- cal correlation. J Gastroenterol Hepatol 2001;16:190-5.
• Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte ste- atosis ia a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-15.
• Kumar D, Farrel GC, Fung C, et al. Hematitis C virus gen- otype 3 is cytopathic to hepatocytes.Genotype specific reversal of hepatic steatosis after sustained response to antiviral therapy. Hepatology 2002;36:1266-72.
• Poynard T, Ratziu V, McHutchison J. et al. Effect of treat- ment with peginterferon or interferon alfa-2b and riba- virin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
• Adinolfi LE, Gambardella A, Tripodi MF, Utili R, Ruggiero G, Andreana A. Steatosis accelerates the progession of liver damage of chronic hepatitis C patients and corre- lates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
• Lagging LM, Garcia CE, Westin J, et al. Comparison of serum hepatitis C virus RNA and core antigen concentra- tions and determination of whether levels are associated with liver histology or affected by specimen stroge time. J Clin Microbiol 2002;40:4224-9.
• Bressler BL, Guindi M, Tomlinson G, Heatcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-44.
• Giannini E, Ceppa P, Testa R. Steatosis in chronic hepatitis C: Can weight reduction improve therapeutic efficacy. J Hepetol 2001;35:432-3.